{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T05:07:27Z","timestamp":1734412047531,"version":"3.30.2"},"reference-count":38,"publisher":"Pan American Health Organization","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,16]]},"DOI":"10.26633\/rpsp.2024.94","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T11:42:28Z","timestamp":1734349348000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Seguridad de las vacunas contra la COVID-19: resultados de vigilancia activa en una unidad centinela en Argentina"],"prefix":"10.26633","volume":"48","author":[{"given":"Nerina Ivana","family":"Lescura","sequence":"first","affiliation":[{"name":"Departamento de Epidemiolog\u00eda, Hospital Provincial Neuqu\u00e9n, Dr. Castro Rend\u00f3n, Neuqu\u00e9n, Argentina."},{"name":"nlescura@hospitalneuquen.org.ar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Selent","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Naci\u00f3n, Ciudad Aut\u00f3noma de Buenos Aires, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Noel","family":"Guerci","sequence":"additional","affiliation":[{"name":"Departamento de Epidemiolog\u00eda, Hospital Provincial Neuqu\u00e9n, Dr. Castro Rend\u00f3n, Neuqu\u00e9n, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavia Mar\u00eda","family":"Bertachini","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Naci\u00f3n, Ciudad Aut\u00f3noma de Buenos Aires, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Victoria","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Naci\u00f3n, Ciudad Aut\u00f3noma de Buenos Aires, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Martina","family":"de Prada","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Naci\u00f3n, Ciudad Aut\u00f3noma de Buenos Aires, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"del Valle Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Departamento de Epidemiolog\u00eda, Hospital Provincial Neuqu\u00e9n, Dr. Castro Rend\u00f3n, Neuqu\u00e9n, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy Vivian","family":"Barboza","sequence":"additional","affiliation":[{"name":"Departamento de Epidemiolog\u00eda, Hospital Provincial Neuqu\u00e9n, Dr. Castro Rend\u00f3n, Neuqu\u00e9n, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda del Valle","family":"Ju\u00e1rez","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Naci\u00f3n, Ciudad Aut\u00f3noma de Buenos Aires, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anal\u00eda Florencia","family":"C\u00e1ceres","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n Panamericana de la Salud, Washington D.C., Estados Unidos de Am\u00e9rica."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Falla","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n Panamericana de la Salud, Washington D.C., Estados Unidos de Am\u00e9rica."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivonne Natalia","family":"Solarte","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n Panamericana de la Salud, Washington D.C., Estados Unidos de Am\u00e9rica."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florencia","family":"Bruggesser","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Naci\u00f3n, Ciudad Aut\u00f3noma de Buenos Aires, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Stecher","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Naci\u00f3n, Ciudad Aut\u00f3noma de Buenos Aires, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11167","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Sohrabi C, Alsafi Z, O\u2019Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71-6.","DOI":"10.1016\/j.ijsu.2020.02.034"},{"key":"ref2","unstructured":"Organizaci\u00f3n Mundial de la Salud. WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination. Disponible en: https:\/\/www.who.int\/publications-detail-redirect\/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination"},{"key":"ref3","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Manual de vigilancia de eventos supuestamente atribuibles a la vacunaci\u00f3n o inmunizaci\u00f3n en la Regi\u00f3n de las Am\u00e9ricas. Washington D.C.: OPS: 2021. Disponible en: https:\/\/iris.paho.org\/handle\/10665.2\/55384"},{"key":"ref4","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Protocolo para la vigilancia centinela de la seguridad de las vacunas contra la COVID-19. Washington D.C.: OPS; 2022. Disponible en: https:\/\/iris.paho.org\/handle\/10665.2\/57378"},{"key":"ref5","unstructured":"Ministerio de Salud. Banco de recursos de comunicaci\u00f3n. Lineamientos t\u00e9cnicos de la campa\u00f1a de vacunaci\u00f3n contra el COVID-19. Ciudad Aut\u00f3noma de Buenos Aires: Ministerio de Salud de la Naci\u00f3n; 2021. Disponible en: https:\/\/bancos.salud.gob.ar\/recurso\/lineamientos-tecnicos-de-la-campana-de-vacunacion-contra-el-covid-19"},{"key":"ref6","unstructured":"Argentina.gob.ar. \u00bfCu\u00e1les vacunas aplicamos en el pa\u00eds? 2021. Disponible en: https:\/\/www.argentina.gob.ar\/coronavirus\/vacuna\/cuales"},{"key":"ref7","unstructured":"Organizaci\u00f3n Mundial de la Salud. COVID-19 vaccine tracker and landscape. Ginebra: OMS; 2023. Disponible en: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Phillips A, Jiang Y, Walsh D, Andrews N, Artama M, Clothier H, et al. Background rates of adverse events of special interest for COVID-19 vaccines: a multinational Global Vaccine Data Network (GVDN) analysis. Vaccine. 2023;41(42):6227-38.","DOI":"10.1016\/j.vaccine.2023.08.079"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Myers TR, Marquez PL, Gee JM, Hause AM, Panagiotakopoulos L, Zhang B, et al. The v-safe after vaccination health checker: active vaccine safety monitoring during CDC\u2019s COVID-19 pandemic response. Vaccine. 2023;41(7):1310-8.","DOI":"10.1016\/j.vaccine.2022.12.031"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Psihogios A, Brianne Bota A, Mithani SS, Greyson D, Zhu DT, Fung SG, et al. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: a Canadian immunization research network study. Vaccine. 2022;40(31):4065-80.","DOI":"10.1016\/j.vaccine.2022.04.103"},{"key":"ref11","unstructured":"Ministerio de Salud de la Provincia del Neuqu\u00e9n. Organizaci\u00f3n sectorial. Disponible en: https:\/\/www.saludneuquen.gob.ar\/organizacion-sectorial\/"},{"key":"ref12","unstructured":"Organizaci\u00f3n Mundial de la Salud. Clasificaci\u00f3n estad\u00edstica internacional de enfermedades y problemas relacionados con la salud, d\u00e9cima revisi\u00f3n. Washington, D.C: OPS; 1995"},{"key":"ref13","unstructured":"Safety Platform for Emergency Vaccines. COVID-19. Disponible en: https:\/\/speacsafety.net\/tools\/aesi-lists\/covid-19\/"},{"key":"ref14","unstructured":"Grupo Colaborador Brighton. Case definitions table view. Disponible en: https:\/\/brightoncollaboration.org\/case-definitions-table-view\/"},{"key":"ref15","unstructured":"Ministerio de Salud. Banco de recursos de comunicaci\u00f3n. 20\u00b0 Informe de seguridad en vacunas. Ciudad Aut\u00f3noma de Buenos Aires, Ministerio de Salud de la Naci\u00f3n. Disponible en: https:\/\/bancos.salud.gob.ar\/recurso\/20deg-informe-de-seguridad-en-vacunas"},{"key":"ref16","unstructured":"Gov.uk. Coronavirus (COVID-19) vaccines adverse reactions. Disponible en: https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions"},{"key":"ref17","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Informaci\u00f3n regional y global consolidada sobre eventos supuestamente atribuibles a la vacunaci\u00f3n o inmunizaci\u00f3n (ESAVI) contra la COVID-19 y otras actualizaciones. Washington D.C.: OPS. Disponible en: https:\/\/covid-19pharmacovigilance.paho.org\/img\/recursos\/618e9018f1127bb7b3c5f9699.pdf"},{"key":"ref18","unstructured":"Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. Nueva York: Springer Publishing Co; 2005."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-81.","DOI":"10.1016\/S0140-6736(21)00234-8"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15.","DOI":"10.1056\/NEJMoa2034577"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-101.","DOI":"10.1056\/NEJMoa2104840"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331-40.","DOI":"10.1001\/jama.2021.24110"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Karlstad \u00d8, Hovi P, Husby A, H\u00e4rk\u00e4nen T, Selmer RM, Pihlstr\u00f6m N, et al. SARS-CoV-2 vaccination and myocarditis in a Nordic Cohort study of 23 million residents. JAMA Cardiol. 2022;7(6):600-12.","DOI":"10.1001\/jamacardio.2022.0583"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"ref26","unstructured":"Agencia Europea de Medicamentos. AstraZeneca\u2019s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Disponible en: https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood-platelets"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Hunter PR. Thrombosis after covid-19 vaccination. BMJ. 2021;373:n958.","DOI":"10.1136\/bmj.n958"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Potteg\u00e5rd A, Lund LC, Karlstad \u00d8, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114.","DOI":"10.1136\/bmj.n1114"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Principi N, Esposito S. Vaccine-preventable diseases, vaccines and Guillain-Barre\u2019 syndrome. Vaccine. 2019;37(37):5544-50.","DOI":"10.1016\/j.vaccine.2018.05.119"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Jaffry M, Mostafa F, Mandava K, Rosario S, Jagarlamudi Y, Jaffry K, et al. No significant increase in Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study. Vaccine. 2022;40(40):5791-7.","DOI":"10.1016\/j.vaccine.2022.08.038"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Grimshaw M, Ceballos-Liceaga SE, Hern\u00e1ndez-Vanegas LE, N\u00fa\u00f1ez I, Hern\u00e1ndez-Valdivia N, Carrillo-Garc\u00eda DA, et al. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study. Clin Immunol. 2021;229:108786.","DOI":"10.1016\/j.clim.2021.108786"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Keddie S, Pakpoor J, Mousele C, Pipis M, Machado PM, Foster M, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr\u00e9 syndrome. Brain J Neurol. 2021;144(2):682-93.","DOI":"10.1093\/brain\/awaa433"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Blumenthal KG, Robinson LB, Camargo CA, Shenoy ES, Banerji A, Landman AB, et al. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021;325(15):1562-5.","DOI":"10.1001\/jama.2021.3976"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014;13(3):215-24.","DOI":"10.1016\/j.autrev.2013.10.003"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Yazdanpanah F, Iranpour P, Haseli S, Poursadeghfard M, Yarmahmoodi F. Acute disseminated encephalomyelitis (ADEM) after SARS- CoV-2 vaccination: a case report. Radiol Case Rep. 2022;17(5):1789-93.","DOI":"10.1016\/j.radcr.2022.03.013"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Karatzios C, Scuccimarri R, Ch\u00e9deville G, Basfar W, Bullard J, Stein DR. Multisystem Inflammatory syndrome following SARS-CoV-2 vaccination in two children. Pediatrics. 2022;150(2):e2021055956.","DOI":"10.1542\/peds.2021-055956"},{"key":"ref37","unstructured":"Grandis G. Censo Nacional de Poblaci\u00f3n, Hogares y Viviendas 2022: resultados provisorios. Disponible en: https:\/\/censo.gob.ar\/index.php\/censo-2022-resultados-provisorios\/"},{"key":"ref38","unstructured":"Argentina.gob.ar. Monitor p\u00fablico de vacunaci\u00f3n; 2021. Disponible en: https:\/\/www.argentina.gob.ar\/coronavirus\/vacuna\/aplicadas"}],"container-title":["Revista Panamericana de Salud P\u00fablica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/62473\/v48e942024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T11:43:13Z","timestamp":1734349393000},"score":1,"resource":{"primary":{"URL":"https:\/\/iris.paho.org\/handle\/10665.2\/62473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":38,"alternative-id":["RPSP.2024.94"],"URL":"https:\/\/doi.org\/10.26633\/rpsp.2024.94","relation":{},"ISSN":["1020-4989","1680-5348"],"issn-type":[{"value":"1020-4989","type":"print"},{"value":"1680-5348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}